Polycystic Ovary Syndrome and Fibrocystic Breast Disease: An Updated Review

Michał Kunicki; Roman Smolarczyk

doi:10.1055/a-1392-0938

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2021; 53(04): 219-224
DOI: 10.1055/a-1392-0938

Review

Polycystic Ovary Syndrome and Fibrocystic Breast Disease: An Updated Review

Michał Kunicki

¹Department of Gynecological Endocrinology, Medical University of Warsaw, Warsaw, Poland

²Invicta Private Fertility Center, Warsaw, Poland

,

Roman Smolarczyk

¹Department of Gynecological Endocrinology, Medical University of Warsaw, Warsaw, Poland

› Institutsangaben

Abstract

Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age. There is no clear association between PCOS and benign breast disease (BBD). The latter is a frequent benign disorder, affecting women between 20 and 50 years of age. To date, the classification remains controversial, and the risk of developing breast cancer that is associated with these changes is different depending on the histopathological findings. The most frequent changes are breast cysts, which are noted in up to 50% of patients older than 30 years of age. This up-to-date review presents the relationship between PCOS and BBD. In conclusion, there is no clear association between benign breast disease and PCOS. Further studies on a large population with prospectively collected data using updated PCOS criteria are necessary.

Key words

polycystic ovarian syndrome - benign breast disease - fibrocystic breast changes - obesity - insulin resistance

Volltext

Referenzen

References
1 Teede HJ. Recommendations from the international evi- dence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018; 33: 1602-1618 Erratum: Hum Reprod 2019; 34: 388
2 Escobar-Morreale HF. Polycystic ovary syndrome: Deﬁnition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14: 270-284
3 Dumesic DA, Oberfield SE, Stener-Victorin E. etal. Scientiﬁc statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 2015; 36: 487-525
4 Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: Phenotype and adiposity impact. Trends Endocrinol Metab 2015; 26: 136-143
5 Rotterdam ESHRE/ASRM-Sponosored PCOS Consensus Work shop Group (2004) Revised 2003 consensus on diagnostic cri teria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47
6 Lefebvre P, Raingeard I, Renard E. et al. Long-term risks of polycysticovaries syndrome. Gynecol Obstet Fertil 2004; 32: 193-198
7 Welt CK, Gundmudsson JA, Aranon G. et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006; 41: 4842-4848
8 Carmina E, Wong L, Chang L. et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997; 12: 905-909
9 Iftikhar S, Collazo-Clavell ML, Roger VL. et al. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med 2012; 70: 74-80
10 Legro RS, Gnatuk CL, Kunselman AR. et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: A controlled study. J Clin Endocrinol Metab 2005; 90: 3236-3242
11 Moran LJ, Misso ML, Wild RA. et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-363
12 Diamanti-Kandarakis E, Kouli C, Alexandraki K. et al. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clinl Endocrinol Metab 2004; 89: 1273-1276
13 Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; 113: 1148-1159
14 Fisher SA, Reid RL, Van Vugt DA. et al. A random- ized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 2002; 78: 280-285
15 Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2006; 86: S13-S14
16 Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110-3116
17 Gadalla MA, Norman RJ, Tay CT. al. Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Int J Fertil Steril 2020; 4: 257-270
18 Joham AE, Palomba S. et al. Polycystic ovary syndrome, obesity, and pregnancy. Semin Reprod Med 2016; 34: 93-101
19 Palomba S, de Wilde MA, Falbo A. et al. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update 2015; 21: 575-592
20 Walters KA, Gilchrist RB, Ledger WL. et al. New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol Metab 2018; 29: 841-852
21 Paris VR, Bertoldo MJ. The Mechanism of Androgen Actions in PCOS Etiology. J Med Sci (Basel) 2019; 7: 89
22 Livadas S, Pappas C, Karachalios A. et al. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine 2014; 47: 631-638
23 Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev 2016; 5: 467–520.
24 Keefe CC, Goldman MM, Zhang K. et al. Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spec-trometry. PLoS One 2014; 9: e93805
25 Sullivan, S.D. and Moenter, S.M Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci U. S. A. 2004; 101: 7129–7134
26 Herbison AE, Moenter SM. Depolarising and hyper- polarising actions of GABA(A) receptor activation on gonadotrophin-releasing hormone neurones: Towards an emerging consensus. J. Neuroendocrinol 2011; 23: 557-569
27 Wang T, Han S, Tian W. et al. Effects of kisspeptin on pathogenesis and energy metabolism in polycystic ovarian syndrome (PCOS). Gynecol Endocrinol 2019; 35 9 807-881
28 Wang F, Niu WB, Kong HJ. et al. The role of AMH and its receptor SNP in the pathogenesis of PCOS. Mol Cell Endocrinol 2017; 439: 363-368
29 Filippou P, Homburg R. Is foetal hyperexposure to androgens a cause of PCOS?. Hum Reprod Update 2017; 23: 421-432
30 Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. 2nd Ed.. London: W. B. Saunders; 2000: 123-135
31 Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151
32 Courtillot C, Plu-Bureau NBinart. et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 2005; 10: 325-335
33 Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 1997; 19: 310-327
34 Guray M, Sahin A. Benign breast Disease: Classification, Diagnosis and Management. Oncologist 2006; 11: 435-449
35 Stachs A, Stubert J, Reimer T. et al. Benign Breast Disease in Women. Dtsch Arztebl Int 2019; 116: 565-574
36 Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am 2002; 29: 1-20
37 Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005; 353: 275-285
38 Collins LC, Aroner SA, Connolly JL. et al. Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses’ Health Studies. Cancer 2016; 122: 515-520
39 Hislop TG, Elwood JM. Risk factors for benign breast disease: A 30-year cohort study. Can Med Assoc J 1980; 124: 283-291
40 Fiorica JV. Fibrocystic changes. Obstet Gynecol clin North Am 1994; 21: 445-485
41 Sitruk- Ware LR, Stenkers N, Mowszowicz I. et al. Inadequate corpus luteal function in women with benign breast disease. J Clin Endocrinol Metab 1977; 44: 771-774
42 Ayers JWT, Gidwani GP. The “Luteal breast” hormonal and sonographic investigation of benign breast disease in patients with cyclic mastalgia. Fertili Steril 1983; 40: 779-784
43 Burrows C, Holly JM, Laurence NJ. et al. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 2006; 147: 3484-3500
44 Rohan TE, Cook MG, Potter JD. et al. A case-control study of diet and benign proliferative epithelial disorders of the breasts. Cancer Res 1990; 50: 3176-3181
45 Hislop TG, Band PR, Deschamps M. et al. Diet and histologic types of benign breast disease definied by subsequent risk of breast cancer. Am J Epidemiol 1990; 131: 263-270
46 Ingram DM, Nottage E, Roberts T. The role of diet in the development of breast cancer: a case-control study of patients with breast cancer, benign epithelial hyperplasia and fibrocystic disease of breasts. Br J Cancer 1991; 64: 187-191
47 Parazzini F, Ferraroni M, La Vecchia C. et al. Smoking habits and risk of benign breast disease. Int J Epidemiol 1991; 20: 430-434
48 Parazzini F, La Vecchia C, Franceschi S. et al. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984; 120: 115-122
49 Santen RJ. In: Benign Breast Disease in Women. Feingold KR, Anawalt B, Boyce A. et al. (eds). Endotext [Internet] South Dartmouth (MA): MDText.com, Inc.;
50 Samoli E, Trichopoulos DA, Lagiou A. et al. The hormonal profile of benign breast disease. Br J Cancer 2013; 108: 199-204
51 Katz E, Adashi EY. Hyperprolactinemic disorders. Clin Obstet Ginecol 1990; 33: 622-639
52 Branchini G, Schneider L, Cericatto R. et al. Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas. Endocrine 2009; 35: 459-466
53 Brkić M, Vujović S, Ivović M. et al. The role of E2/P ratio in the etiology of fibrocystic breast disease, mastalgia and mastodynia. Acta Clin Croat 2018; 57: 756-761
54 Mady EA. Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. J Steroid Biochem Mol Biol 2000; 75: 323-328
55 Carvalho MJ, Subtil S, Rodrigues Â. et al. Controversial association between polycystic ovary syndrome and breast cancer. Eur J Obstet Gynecol Reprod Biol 2019; 243: 125-132
56 Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009; 11: 212 Review
57 Noroozzadeh M, Behboudi-Gandevani S, Mosaffa N. et al. High prevalence of benign mammary tumors in a rat model of polycystic ovary syndrome during postmenopausal period. Gynecol Endocrinol 2019; 358: 679-684
58 Carlstroem K, Doeberl A, Gershagen S. et al. Elevated peripheral levels of androgens and of some steroid sensitive plasma proteins in patients with severe fibrocystic breast disease: a preliminary report. Acta Obstet Gynecol Scand Suppl 1984; 63: 157-158
59 Wang DY, Fentiman IS. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 1985; 6: 5-36
60 Delcour C, Robin G, Young J. et al. PCOS and Hyperprolactinemia: what do we know in 2019?. Clin Med Insights Reprod Health 2019; 13: 1179558119871921 eCollection 2019, Review
61 Sieja K, Stanosz S. The concentrations of prolactin and estrogens in women with fibrocystic changes in the breast. Ginekol Pol 2002; 73: 594-599
62 Peters F, Schuth W, Scheurich B. et al. Serum prolactin levels in patients with fibrocystic breast disease. Obstet Gynecol 1984; 64: 381-385
63 Sitruk-Ware R, Clair F, Sterkers N. et al. Prolactin secretion in benign breast diseases. Gynecol Endocrinol 1987; 1: 195-200
64 Angelousi A, Diamanti-Kandarakis E, Zapanti E. et al. Is there an association between thyroid function abnormalities and breast cancer?. Arch Endocrinol Metab 2017; 61: 54-61
65 Gaberšček S, Zaletel K, Schwetz V. et al. Mechanisms in endocrinology: thyroid and polycystic ovary syndrome. Eur J Endocrinol 2015; 172: R9-R21
66 Chen YY, Fang WH, Wang CC. et al. Examining the Associations among Fibrocystic Breast Change, Total Lean Mass, and Percent Body Fat. Sci Rep 2018; 15: 9180
67 D’Amelio R, Farris M, Grande S. et al. Association between polycystic ovary and fbrocystic breast disease. Gynecol Obstet Invest 2001; 51: 134-137
68 Franks S. In: Morphology of the polycystic ovary. Dunaif A, Givens J. The Polycystic Ovary Syndrome. London: Blackwell Scientific Publications; 1992
69 Dewailly D, Lujan ME, Carmina E. et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014; 20: 334-352
70 Gumus II, Koktener A, Dogan D. et al. Polycystic ovary syndrome and fibrocystic breast disease: is there any association?. Arch Gynecol Obstet 2009; 280: 249-253
71 Soran A, Talbott EO, Zborowski JV. et al. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract 2005; 59: 795-797
72 Ozkaya E, Cakir E, Cinar M. et al. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?. Gynecol Endocrinol 2012; 8: 468-471
73 Brodell LA, Mercurio MG. Hirsutism: diagnosis and management. Gend Med 2010; 7: 79-87
74 Sarac ZF. Association between insulin resistance and breast parenchyma in women with polycystic ovary syndrome. Turk J Endocrinol Metab 2012; 16: 1-5
75 Eslami B, Alipour S, Hosseini R. et al. Breast density in polycystic ovarian syndrome patients: A case-control study. Int J Reprod Biomed (Yazd) 2019; 3: 577-584
76 Rao AA, Feneis J, Lalonde C. et al. Pictorial Review of Changes in the BI-RADS Fifth Edition. Radiographics 2016; 36: 623-639

Zusatzmaterial

Supplementary Material